Genentech: OCREVUS Early Initiation of Treatment Cuts Disability Progression

• People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less disability progression vs. those who switched from interferon beta-1α
• People with primary progressive MS (PPMS) treated with OCREVUS earlier had less disability and upper limb progression than those who switched from placebo
• Longer-term safety data are consistent with OCREVUS’ favorable benefit-risk profile for both RMS and PPMS
• OCREVUS approved in 68 countries, with over 70,000 patients treated globally

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS^® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 10-12 in Berlin, Germany. Five-year data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO show OCREVUS efficacy is maintained on key measures of disease activity and that people treated earlier with OCREVUS had superior disability progression outcomes compared with RMS patients who switched from interferon beta-1α or PPMS patients who switched from placebo.

https://www.businesswire.com/news/home/20181009006218/en/OCREVUS-Ocrelizumab-Data-Show-Early-Initiation-Treatment